Single Cell Consumables was 10x Genomics’s largest product and service line in fiscal 2025, bringing in $363.21M of $642.82M (57%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Chromium Consumables | $400.43M | — | — | — | |||||
| Single Cell Consumables | — | $420.32M | $372.31M | $363.21M | |||||
| Consumables | — | — | — | — | |||||
| Spatial Consumables | $35.16M | $59.24M | $121.12M | $143.98M | |||||
| Chromium Instruments | $58.55M | — | — | — | |||||
| Spatial Instruments | $13.84M | $75.61M | $57.50M | $34.11M | |||||
| Single Cell Instruments | — | $47.87M | $35.21M | $22.67M | |||||
| Instruments | — | — | — | — | |||||
| Instuments | — | — | — | — | |||||
| License & Royalty Revenue | — | — | $321.00K | $46.14M | |||||
| Services | $8.43M | $15.70M | $24.32M | $32.73M | |||||
| Service | — | — | — | — | |||||
| Total | $516.41M | $618.73M | $610.79M | $642.82M |
10x Genomics brought in $642.82M from its six product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 5.2% from $610.79M in fiscal 2024. Single Cell Consumables was the largest at $363.21M (56.5%), ahead of Spatial Consumables at $143.98M (22.4%) and License & Royalty Revenue at $46.14M (7.2%). The other three lines brought in $89.51M combined.
Compared with fiscal 2024, License & Royalty Revenue grew fastest, up 14,272.3% to $46.14M, while Spatial Instruments fell the most, down 40.7% to $34.11M.
10x Genomics began breaking out Single Cell Consumables in fiscal 2023, Single Cell Instruments in fiscal 2023 and License & Royalty Revenue in fiscal 2024. 10x Genomics stopped reporting Chromium Consumables ($400.43M in fiscal 2022) and Chromium Instruments ($58.55M in fiscal 2022) as separate lines.
United States was 10x Genomics’s largest region in fiscal 2025, bringing in $346.51M of $642.82M (54%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| United States | $284.99M | $360.09M | $334.32M | $346.51M | |||||
| Europe, Middle East & Africa | $117.07M | $142.28M | $159.76M | $161.72M | |||||
| North America | — | — | — | — | |||||
| Asia-Pacific (Excluding China) | $41.21M | $52.29M | $45.96M | $52.07M | |||||
| China | $64.36M | $50.97M | $57.30M | $70.26M | |||||
| Asia-Pacific | — | — | — | — | |||||
| Asia Pacific | — | — | — | — | |||||
| Americas (Excluding United States) | $8.79M | $13.10M | $13.45M | $12.26M | |||||
| North America (Excluding United States) | — | — | — | — | |||||
| Total | $516.41M | $618.73M | $610.79M | $642.82M |
10x Genomics brought in $642.82M from its five regions in fiscal 2025, the year ended December 31, 2025. That was up 5.2% from $610.79M in fiscal 2024. United States was the largest at $346.51M (53.9%), ahead of Europe, Middle East & Africa at $161.72M (25.2%) and China at $70.26M (10.9%). The other two regions brought in $64.33M combined.
Compared with fiscal 2024, China grew fastest, up 22.6% to $70.26M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $516.41M to $642.82M, a compound annual growth rate of 7.6%. United States' share of the total fell from 55.2% to 53.9%.
10x Genomics (TXG) reports its revenue by product and service and by geography. In fiscal 2025, Single Cell Consumables was its largest product and service line, bringing in $363.21M (56.5% of the total), followed by Spatial Consumables at $143.98M (22.4%).
Single Cell Consumables was 10x Genomics' largest product and service line in fiscal 2025, bringing in $363.21M, or 56.5% of the $642.82M total across its six product and service lines.
United States was 10x Genomics' largest region in fiscal 2025, bringing in $346.51M, or 53.9% of the $642.82M total across its five regions.
Among 10x Genomics' product and service lines that make up at least 2% of revenue, License & Royalty Revenue grew fastest in fiscal 2025, up 14,272.3% from $321.00K to $46.14M.
Every figure comes from 10x Genomics' annual financial filings, as reported. Each line keeps the name 10x Genomics gives it, and years follow its fiscal calendar.
10x Genomics' revenue by product and service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.